Several drugs approved to treat type 2 diabetes may lead to ketoacidosis, a serious condition that may require hospitalization, the FDA has warned.
The medications named in the safety announcement—canagliflozin, dapagliflozin, and empagliflozin—belong to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class of drugs that are FDA-approved for use with diet and exercise to lower blood glucose levels in adults with type 2 diabetes. The SGLT2 inhibitors lower blood glucose levels by causing the kidneys to remove glucose from the body through urine.
Voelker R. Diabetes Drug Warning. JAMA. 2015;314(1):17. doi:10.1001/jama.2015.6849